On December 2, YOZY Bio (02496) issued an announcement stating that the results of its independently developed bispecific antibody drug M701 in the Phase II clinical trial in China have been published in the internationally renowned medical journal Experimental Hematology & Oncology.

This study included 84 patients, of whom 43 received intraperitoneal infusion of M701. The median puncture-free survival was 75 days in the M701 group and 25 days in the control group, a significant difference (p=0.0065). The 6-month survival rate was 33.3% in the M701 group and 12.1% in the control group. No other serious adverse events were observed in the M701 group.

M701 is a bispecific antibody that targets the tumor cell target EpCAM and the immune T cell activation target CD3, aiming to eliminate tumor cells in the peritoneal cavity by activating T cells. Currently, M701 is undergoing multiple clinical trials at different stages for malignant ascites and malignant pleural effusion.

The company has granted Chia Tai Tianqing Pharmaceutical Group Co., Ltd. an exclusive license in China to develop, register, manufacture and commercialize any product containing M701.

https://finance.eastmoney.com/a/202512023580482131.html